We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
APOTEX-ZOLEDRONIC (Apotex Pty Ltd)
Product name
APOTEX-ZOLEDRONIC
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
177 (255 working days)
Active ingredients
Zoledronic acid monohydrate
Registration type
EOI
Indication
As an adjunct to adjuvant treatment for women with early breast cancer who are in established menopause.